SuperworthAccuray ARAY
- Market cap
- $15.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $401.9M
- −12% on a year ago
- Net margin
- −12.2%
- Free cash flow yield
- −82.6%
Accuray trades at 0.0× sales. Revenue was $401.9M over the last twelve months, down 12% on a year earlier with a −12% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $103.9M+8% | $107.2M−7% | $101.1M−14% | $134.3M+14% | $101.5M−2% | $116.2M+8% | $113.2M+12% | $127.5M−5% | $93.9M−8% | $102.2M−12% | $104.8M−7% | $100.9M−21% | |
| Cost of revenue | $64.4M+4% | $71.3M−1% | $72.1M−9% | $95.8M+19% | $67.1M+4% | $74.3M+4% | $81.6M+13% | $88.6M−8% | $67.4M+1% | $78.2M+5% | $79.6M−3% | $65.8M−26% |
| Gross profit | $39.5M+14% | $35.9M−16% | $29.1M−25% | $38.5M+2% | $34.5M−13% | $41.9M+17% | $31.6M+9% | $39M+1% | $26.5M−23% | $24.1M−43% | $25.3M−20% | $35.1M−10% |
| R&D | $14M−1% | $15.3M+4% | $10.9M−23% | $9.5M−33% | $12.1M−14% | $13.6M−11% | $10.7M−2% | $11.5M+20% | $11.4M−6% | $10.7M−22% | $8.2M−24% | $7.7M−33% |
| SG&A | $23.3M+3% | $24.6M−4% | $22.7M+2% | $22.1M−8% | $24.5M+5% | $23.5M−4% | $19.9M−13% | $23.3M+5% | $26.5M+8% | $18.9M−20% | $19.7M−1% | $21.1M−9% |
| $2.2M | −$4M | −$4.6M | $6.8M | −$2.1M | $4.7M | $1M | $4.2M−38% | −$11.3M+426% | −$11.6M | −$9.1M | $5.5M+31% | |
| Interest expense | $2.9M+29% | $2.9M+11% | $2.9M+6% | $2.9M−4% | $3M+1% | $2.9M−1% | $2.9M+0% | $4.2M+46% | $8.1M+173% | $7.7M+167% | $8.4M+192% | $8.7M+106% |
| Pre-tax income | −$1M−80% | −$8.7M+960% | −$5.9M | $3.9M | −$3.3M+221% | $3.2M | −$840K−86% | $2.1M−46% | −$21.2M+537% | −$13.2M | −$11.3M+1250% | −$1.5M |
| $1.9M+467% | $878K−16% | $444K−15% | $471K−19% | $625K−68% | $695K−21% | $457K+3% | $948K+101% | $471K−25% | $573K−18% | $468K+2% | $434K−54% | |
| Net income | −$3M−46% | −$9.6M+413% | −$6.3M | $3.4M | −$4M+33% | $2.5M | −$1.3M−80% | $1.1M−67% | −$21.7M+448% | −$13.8M | −$11.8M+810% | −$1.9M |
| −$0.03−50% | −$0.10+400% | −$0.06 | $0.03 | −$0.04+33% | $0.02 | −$0.01−83% | $0.01−67% | −$0.18+350% | −$0.11 | n/a | n/a | |
| 96.6M+3% | 97.8M+3% | 99.2M+2% | 99.6M+4% | 100.2M+4% | 103.7M+6% | 102.8M+4% | 106.7M+7% | 118.9M+19% | 121M+17% | n/a | n/a |
Net income: 21 periods, Q2 FY13 to Q2 FY18: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY11 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Accuray's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARAYAccuray | $15.5M | n/m | 71.4× | 0.0× | −12% | −12.2% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on Accuray
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 116Medical instruments and supplies stocks with the lowest price to sales ratio
- #6of 496Healthcare stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .